Sucampo Pharmaceuticals, Inc. is dedicated to developing and commercializing safe, innovative pharmacological treatments that enhance the quality of human life.

Our research and development focuses on developing prostones with novel mechanism of action for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders for which there are unmet and underserved medical needs and significant commercial potential.

Our strategy to achieve this objective includes:

• Focus on commercial launch of AMITIZA™ in the U.S. for the treatment of chronic idiopathic constipation.
• Develop AMITIZA™ for the treatment of additional indications and develop and commercialize other prostone product candidates. We believe that our focus on prostones may offer several potential advantages including:
• novel mechanism of action;
• wide-ranging therapeutic potential;
• discovery and development experience; and
• patent protection
• Target large and underserved markets.
• Seek marketing approval for AMITIZA™ and our product candidates in Europe and the Asia-Pacific region.
• Focus on our core clinical development and commercialization activities.
• Grow through strategic acquisitions and in-licensing opportunities.